Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.
Augustin A, Le Gouill S, Gressin R, Bertaut A, Monnereau A, Woronoff AS, Trétarre B, Delafosse P, Troussard X, Moreau A, Hermine O, Maynadié M. Augustin A, et al. Among authors: gressin r. J Cancer Res Clin Oncol. 2018 Apr;144(4):629-635. doi: 10.1007/s00432-017-2529-9. Epub 2017 Oct 11. J Cancer Res Clin Oncol. 2018. PMID: 29022078 Clinical Trial.
Clinical and biologic features of CD4(+)CD56(+) malignancies.
Feuillard J, Jacob MC, Valensi F, Maynadié M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drénou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, Le Calvez G, Sainty D, Sotto MF, Trimoreau F, Béné MC. Feuillard J, et al. Among authors: gressin r. Blood. 2002 Mar 1;99(5):1556-63. doi: 10.1182/blood.v99.5.1556. Blood. 2002. PMID: 11861268 Free article.
High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.
Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, Escoffre-Barbe M, Maisonneuve H, Delwail V, Gressin R, Legouffe E, Vilque JP, Desablens B, Jaubert J, Ramee JF, Jenabian A, Thyss A, Le Pourhiet-Le Mevel A, Travade P, Delepine R, Colombat P; GOELAMS. Deconinck E, et al. Among authors: gressin r. Blood. 2005 May 15;105(10):3817-23. doi: 10.1182/blood-2004-10-3920. Epub 2005 Feb 1. Blood. 2005. PMID: 15687232 Free article. Clinical Trial.
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; French GOELAMS Group. Gressin R, et al. Haematologica. 2010 Aug;95(8):1350-7. doi: 10.3324/haematol.2009.011759. Epub 2010 Mar 10. Haematologica. 2010. PMID: 20220059 Free PMC article. Clinical Trial.
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, Morineau N, Jardel H, Moreau P, Gallazini-Crépin C, Gries P, Gressin R, Harousseau JL, Mohty M, Moreau P, Kraeber-Bodere F, Le Gouill S. Bodet-Milin C, et al. Among authors: gressin r. Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42. doi: 10.1007/s00259-010-1469-2. Epub 2010 Apr 29. Eur J Nucl Med Mol Imaging. 2010. PMID: 20428863
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R. Simon A, et al. Among authors: gressin r. Br J Haematol. 2010 Oct;151(2):159-66. doi: 10.1111/j.1365-2141.2010.08329.x. Epub 2010 Aug 25. Br J Haematol. 2010. PMID: 20738307 Free article. Clinical Trial.
Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.
Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G; GELA and GOELAMS. Le Gouill S, et al. Among authors: gressin r. Haematologica. 2011 Aug;96(8):1128-35. doi: 10.3324/haematol.2010.030320. Epub 2011 Apr 12. Haematologica. 2011. PMID: 21486862 Free PMC article. Clinical Trial.
Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
Gimenez E, Chauvet M, Rabin L, Puteaud I, Duley S, Hamaidia S, Bruder J, Rolland-Neyret V, Le Gouill S, Tournilhac O, Voog E, Maisonneuve H, Jacob MC, Leroux D, Béné MC, Formisano-Tréziny C, Gabert J, Gressin R, Callanan MB. Gimenez E, et al. Among authors: gressin r. Br J Haematol. 2012 Jul;158(2):186-197. doi: 10.1111/j.1365-2141.2012.09161.x. Epub 2012 May 25. Br J Haematol. 2012. PMID: 22626453 Free article. Clinical Trial.
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Damaj G, et al. Among authors: gressin r. J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29. J Clin Oncol. 2013. PMID: 23109692 Clinical Trial.
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
Gyan E, Damotte D, Courby S, Sénécal D, Quittet P, Schmidt-Tanguy A, Banos A, Le Gouill S, Lamy T, Fontan J, Maisonneuve H, Alexis M, Dreyfus F, Tournilhac O, Laribi K, Solal-Céligny P, Arakelyan N, Cartron G, Gressin R; GOELAMS Group. Gyan E, et al. Among authors: gressin r. Br J Haematol. 2013 Jul;162(2):240-9. doi: 10.1111/bjh.12379. Epub 2013 May 21. Br J Haematol. 2013. PMID: 23692641 Free article. Clinical Trial.
133 results